Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ODTX · NASDAQ · Biological Products, (No Diagnostic Substances) · No 10-K yet
Odyssey Therapeutics (ODTX) · oqro.io/stocks/ODTX · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Odyssey Therapeutics is on record in SEC filings since 2006.
No open-market sale by an insider of Odyssey Therapeutics (ODTX) was filed with the SEC in the last 90 days.
No trade in Odyssey Therapeutics (ODTX) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$19.14−0.96 (−4.78%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
+16.6% (+$2.72) from May 8, 2026 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $16.42 on May 8, 2026 to $19.14 on Nov 13, 2026 (+16.6%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 2 13F position changes for 1 quarter ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Boston, MA. Listed, but no annual report (10-K) filed yet under this SEC registration.
Last 12 months
Not enough history
Market value
$920M
Short interest: 3.35M shares sold short (7.0% of shares outstanding), +2.0% vs the previous count, 15.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$0
−100.0% vs the same quarter a year earlier
Free cash flow, last 12 months
−$42M
This quarter −$42M, a year earlier −$31.3M
Net debt
—
Debt —, cash $80.6M, at Sep 30, 2026
Net income, last 12 months
—
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Fund moves
4 tracked managers disclosed the same change for Q2 2026. Among this manager's largest new positions for Q2 2026.
Fund moves
4 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since May 8, 2026, ODTX is up 16.6% and the index fund is up 2.3%: 14 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ODTX moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
0 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in ulcerative colitis (uc).
1 trial has a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
On the public record for Odyssey Therapeutics over the 12 months to Nov 14, 2026: 1 clinical trial.
